SHIELD THERAPEUTICS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.35 GBX | +10.20% |
|
-8.47% | -79.85% |
| Feb. 22 | Transcript : Shield Therapeutics plc, 2023 Sales/ Trading Statement Call, Feb 22, 2024 | |
| Feb. 21 | FTSE 100 takes hit ahead of FOMC minutes | AN |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 35.51 | 209.8 | 74.69 | 96.06 | 18.29 | 10.56 | 10.56 | - |
| Enterprise Value (EV) 1 | 25.73 | 205.7 | 71.78 | 84.1 | 18.29 | 13.38 | 27.3 | 22.75 |
| P/E ratio | -15.3 x | -22.4 x | -31.8 x | -4.94 x | -0.41 x | -0.34 x | -0.78 x | 4.22 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 2.99 x | 292 x | 7.19 x | 63.2 x | 4.09 x | 0.85 x | 0.29 x | 0.15 x |
| EV / Revenue | 2.17 x | 286 x | 6.91 x | 55.4 x | 4.09 x | 1.08 x | 0.75 x | 0.32 x |
| EV / EBITDA | -9.14 x | -32.1 x | 130 x | -4.74 x | -0.78 x | -0.58 x | -3.05 x | 1.42 x |
| EV / FCF | - | -38 x | -50.4 x | -4.92 x | - | -0.46 x | -2.03 x | 4.38 x |
| FCF Yield | - | -2.63% | -1.98% | -20.3% | - | -219% | -49.2% | 22.8% |
| Price to Book | - | - | 2.47 x | 2.34 x | - | - | - | - |
| Nbr of stocks (in thousands) | 116,426 | 117,189 | 117,620 | 215,874 | 259,388 | 782,056 | 782,056 | - |
| Reference price 2 | 0.3050 | 1.790 | 0.6350 | 0.4450 | 0.0705 | 0.0135 | 0.0135 | 0.0135 |
| Announcement Date | 4/3/19 | 5/21/20 | 4/29/21 | 6/30/22 | 4/27/23 | - | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 11.88 | 0.719 | 10.39 | 1.519 | 4.467 | 12.37 | 36.3 | 71.13 |
| EBITDA 1 | -2.814 | -6.414 | 0.551 | -17.74 | -23.34 | -22.9 | -8.964 | 15.99 |
| EBIT 1 | -5.168 | -9.035 | -2.154 | -19.95 | -25.71 | -23.31 | -11.63 | 6.947 |
| Operating Margin | -43.5% | -1,256.61% | -20.74% | -1,313.5% | -575.46% | -188.38% | -32.04% | 9.77% |
| Earnings before Tax (EBT) 1 | -5.153 | -9.066 | -1.886 | -19.56 | -40.08 | -25.48 | -12.71 | 11.53 |
| Net income 1 | -1.794 | -8.8 | -2.63 | -19.34 | -40.44 | -27 | -10.9 | 11.8 |
| Net margin | -15.1% | -1,223.92% | -25.32% | -1,272.94% | -905.4% | -218.19% | -30.03% | 16.59% |
| EPS 2 | -0.0200 | -0.0800 | -0.0200 | -0.0900 | -0.1700 | -0.0392 | -0.0174 | 0.003200 |
| Free Cash Flow 1 | - | -5.416 | -1.423 | -17.11 | - | -29.37 | -13.42 | 5.198 |
| FCF margin | - | -753.27% | -13.7% | -1,126.4% | - | -237.34% | -36.98% | 7.31% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 32.5% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 44.05% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 4/3/19 | 5/21/20 | 4/29/21 | 6/30/22 | 4/27/23 | - | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 S1 | 2022 S1 | 2023 S1 |
|---|---|---|---|
| Net sales 1 | 8.919 | 2.031 | 4.334 |
| EBITDA | - | - | - |
| EBIT 1 | - | -11.72 | -11.54 |
| Operating Margin | - | -577.25% | -266.29% |
| Earnings before Tax (EBT) | - | - | - |
| Net income | - | - | - |
| Net margin | - | - | - |
| EPS | - | - | - |
| Dividend per Share | - | - | - |
| Announcement Date | 9/16/20 | 9/8/22 | 9/28/23 |
1GBP in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 2.82 | 16.7 | 12.2 |
| Net Cash position 1 | 9.78 | 4.1 | 2.91 | 12 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | -0.1233 x | -1.867 x | 0.7624 x |
| Free Cash Flow 1 | - | -5.42 | -1.42 | -17.1 | - | -29.4 | -13.4 | 5.2 |
| ROE (net income / shareholders' equity) | - | - | -8.43% | -54.2% | - | - | - | 131% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | 0.2600 | 0.1900 | - | - | - | - |
| Cash Flow per Share 2 | -0 | -0.0300 | -0.0100 | -0.0800 | - | -0.0500 | -0.0200 | 0.0200 |
| Capex 1 | 3 | 1.35 | 0.02 | 0.37 | - | 0.94 | 0.7 | 0.74 |
| Capex / Sales | 25.24% | 187.76% | 0.22% | 24.49% | - | 7.63% | 1.94% | 1.04% |
| Announcement Date | 4/3/19 | 5/21/20 | 4/29/21 | 6/30/22 | 4/27/23 | - | - | - |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.0135
GBP
Average target price
0.02
GBP
Spread / Average Target
+48.15%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -79.85% | 13.15M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- STX Stock
- Financials Shield Therapeutics plc
